The company is targeting the substantial $100 billion virtual care market and has already secured a client base that includes some of the largest and most well-regarded healthcare organizations nationwide.

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology.

Mulvihill's XLVE ETF offers exposure to large-cap US healthcare stocks with 25% leverage used for purchasing additional shares to write options, generating income from option premiums while maintaining close to "full" exposure to underlying portfolio stocks.

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles.